4参考文献[1]SuchyT,StepanJ.Extragenitalendometriosisasasubjectofinterestforthesurgeon[J].Rozhl-Chir,2004,83（5）:239-241.[2]CutnerAS,LazanakisMS,SaridoganE.Laparoscopicovariansuspensiontofacilitatesurgeryforadvancedendometriosis[J].FertilSteril,2004,82（3）:702-704.[3]K.Koga,Y.Takemura,Y.Osuga,etal.Recurrentofovarianendometriomaafterlaparoscopicexcision[J].HumReprod,2006,21（8）:2171.[4]SakamotoY,HaradaT,HorieS,etal.Tumornecrosisfactoralpha-inducedinterleukin-8（IL-8）expressioninendometrioticstromalcellsprobablythroughnuclearfactor-kappaBactivation:gonadotropin-releasinghormoneagonisttreatmentreducedIL-8expression[J].JClinEndocrinolMetab,2003,88（2）:730-735.[5]MatsuzakiS,UeharaS,MurakamiT,etal.Quantitativeanalysisofestrogenreceptoralphaandbetamessengerribonucleicacidlevelsinnormalendometriumandovarianendometrioticcystsusingareal-timereversetranscriptionpolymerasechainreactionassay[J].FertilSteril,2000,74（4）:753-759.[6]IshiharaH,KitawakiJ,KadoN,etal.Gonadotropin-releasinghormoneagonistanddanazolnormalizearomatasecytochromeP450expressionineutopicendometriumfromwomenwithendometriosis,adenomyosis,orleiomyomas[J].FertilSteril,2003,79（3）:735-742.[7]KorayE,LindaR.Useofthirdgenerationgonadotropin-releasinghormoneantagonistsininvitrofertilization-embryotransfer:areview[J].ObstetGynecolSurv,2001,56（9）:576-588.[8]BasilTC,HelenBN.Gonadotropin-releasinghormoneantagonists:inpactofIVFpracticeandpotentialnon-assistedreproductivetechnologyapplications[J].CurrOpinObstetGynecol,2003,15（3）:259-264.[9]JainJ,DuttonC,NicosiaA,etal.Pharmacokinetics,ovulationsuppressionandreturntoovulationfollowingalowerdosesubcutaneousformulationofDepo-Provera（r）[J].Contraception,2004,70（1）:11.[10]BulunSE,FangZ,ImirG,etal.Aromataseandendometriosis[J].SeminReprodMed,2004,22（1）:45-50.[11]AmsterdamLL,GentryW,JobanputraS,etal.Anastrazoleandoralcontraceptives:anoveltreatmentforendometriosis[J].FertilSteril,2005,84（2）:300-304.[12]HeflerLA,GrimmC,vanTrotsenburgM,etal.Roleofthevaginallyadministeredaromataseinhibitoranastrozoleinwomenwithrectovaginalendometriosis:apilotstudy[J].FertilSteril,2005,84（4）:1033.[13]SwisherDK,TagueRM,SeylerDE.Effectsoftheselectiveestrogenreceptormodulatorraloxifeneonexplanteduterinegrowthinrats[J].DrugDevelRes,1995,36（1）:43-45.[14]ChwaliszK,ElgerW,SticklerT,etal.Theeffectsof1-monthadministrationofasoprisnil（J867）,aselectiveprogesteronereceptormodulator,inhealthypremenopausalwomen[J].HumReprod,2005,20（4）:1090-1099.[15]DeMannoD,ElgerW,GargR,etal.Asoprisnil（J867）:aselectiveprogesteronereceptormodulatorforgynecologicaltherapy[J].Steroids,2003,68（4）:1019-1032.[16]NapAW,GriffioenAW,DunselmanGA,etal.Antiangiogenesistherapyforendometriosis[J].JClinEndocrinolMetab,2004,89（3）:1089.[17]EfstathiouJA,SampsonDA,LevineZ,etal.Nonsteroidalantiinflammatorydrugsdifferentiallysuppressendometriosisinamurinemodel[J].FertilSteril,2005,83（1）:171.[18]SoysalS,SoysalME,OzerS,etal.Theeffectsofpostsurgicaladministrationofgoserelinplusanastrozolecomparedtogoserelinaloneinpatientswithsevereendometriosis:aprospectiverandomizedtrial[J].HumReprod,2004,19（1）:160.[19]DmowskiWP,PryM,DingJ.Cycle-specificandcumulativefecundityinpatientswithendometriosiswhoareundergoingcontrolledovarianhyperstimulation-intrauterineinseminationorinvitrofertilization-embryotransfer[J].FertilSteril,2002,78（4）:750-756.
来源：中日友好医院学报作者：肖巍卞美璐
